S.Biomedics Co., Ltd.
S.Biomedics develops proprietary stem cell differentiation and culture platforms, and sells anti-aging products like fillers through its subsidiary S.Tepharm.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2003, S.Biomedics listed on KOSDAQ in 2023 as a stem cell therapeutics venture. Its proprietary platform, built on cell culture and cell aggregate technology, technology for inducing differentiation into specific cells, safety-securing technology to separate undifferentiated and tumorigenic cells, and GMP-certified production facilities, supports development of embryonic stem cell therapies, while its subsidiary S.Tepharm, established in December 2016, manufactures and sells anti-aging aesthetic products such as fillers and fibroblast-culture cosmetics. It is also researching a tissue-regenerating filler combining fillers with cell therapy, and the global stem cell medicine market is projected to grow from USD 13.7 billion (about KRW 19.9 trillion) in 2022 at a 14.9% CAGR to USD 39.93 billion (about KRW 58.8 trillion) by 2030.
Products & technology
- 필러
- 섬유아세포배양액 화장품
Regulatory approvals
data.go.kr1 Korean MFDS drug approvals · 2021
- MFDS drugCureSkin Inj.Revoked2021-07-29Drug · Prescription · Approval202105645
Clinical trials
data.go.kr5 MFDS clinical trial authorisations · 2019–2023 (Phase 1/2a 3 · Phase 1/2 1 · Phase 3 1)
- Phase 1/2aA9-DPC2023-01-12
1 trial site
- Phase 1/2a동종지방유래 중간엽줄기세포 집합체(3D-A)2020-03-17
1 trial site
- Phase 1/2자가피부유래 섬유아세포 집합체(3D-F)2020-02-25
3 trial sites
- Phase 1/2aPSA-NCAM(+) NPC2019-11-28
4 trial sites
- Phase 3큐어스킨2019-10-18
7 trial sites
R&D and key agreements
Source: DART corporate disclosure배아줄기세포 치료제 · 연구개발(고유 플랫폼기술 기반) · Proprietary technology in cell culture, differentiation induction, and safety assurance, supported by GMP-certified production facilities
조직재생 필러 · 연구 진행 중 · Research combining fillers with cell therapy for tissue regeneration
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition